18.90Open18.90Pre Close0 Volume5 Open Interest20.00Strike Price0.00Turnover255.27%IV7.55%PremiumMay 16, 2025Expiry Date16.17Intrinsic Value100Multiplier7DDays to Expiry2.73Extrinsic Value100Contract SizeAmericanOptions Type0.9702Delta0.0054Gamma2.21Leverage Ratio-0.0604Theta0.0035Rho2.15Eff Leverage0.0033Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet